KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,029 | +7.0% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $12,177 | +14.5% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $10,635 | +2.5% | 1,353 | -11.9% | 0.00% | – |
| Q4 2022 | $10,377 | -48.0% | 1,535 | +11.7% | 0.00% | -100.0% |
| Q3 2022 | $19,937 | +47.5% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $13,520 | -33.2% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $20,253 | -71.0% | 1,374 | -73.9% | 0.00% | 0.0% |
| Q4 2021 | $69,775 | -24.2% | 5,274 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $92,031 | -23.8% | 5,274 | +4.7% | 0.00% | -50.0% |
| Q2 2021 | $120,710 | -6.7% | 5,038 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $129,426 | +38.1% | 5,038 | +2.1% | 0.00% | +100.0% |
| Q4 2020 | $93,697 | +326.4% | 4,934 | +397.4% | 0.00% | – |
| Q2 2019 | $21,972 | – | 992 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |